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Abstract
Objective: To examine the efficacy of ziprasidone vs. placebo for the depressive mixed state in patients with bipolar
disorder type II or major depressive disorder (MDD).
Methods: 73 patients were randomized in a double-blinded, placebo-controlled study to ziprasidone (40-160 mg/d) or
placebo for 6 weeks. They met DSM-IV criteria for a major depressive episode (MDE), while also meeting 2 or 3 (but not
more nor less) DSM-IV manic criteria. They did not meet DSM-IV criteria for a mixed or manic episode. Baseline psychotropic
drugs were continued unchanged. The primary endpoint measured was Montgomery- A ˚sberg Depression Rating Scale
(MADRS) scores over time. The mean dose of ziprasidone was 129.7645.3 mg/day and 126.1647.1 mg/day for placebo.
Results: The primary outcome analysis indicated efficacy of ziprasidone versus placebo (p=0.0038). Efficacy was more
pronounced in type II bipolar disorder than in MDD (p=0.036). Overall ziprasidone was well tolerated, without notable
worsening of weight or extrapyramidal symptoms.
Conclusions: There was a statistically significant benefit with ziprasidone versus placebo in this first RCT of any medication
for the provisional diagnostic concept of the depressive mixed state.
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Mixed states in bipolar disorder have long been recognized.
Over a century ago, Weygandt argued that mixed states were the
most common presentations in manic-depressive illness [1]. While
Kraepelin identified pure depression and pure mania, he described
six different mixed states, which he considered more prevalent
than pure mood states [2].
In the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV), the definition of a mixed episode was narrowed,
compared to previous definitions, so as to require full criteria for
both mania and depression. This was not primarily based on
empirical grounds, but rather, according to some members of the
DSM-IV committee [3], to compensate for expansion of the
bipolar diagnosis into other areas (for example inclusion of type II
and rapid cycling definitions).
In the last decade, a number of studies have suggested that the
previous broader definitions of mixed states may have diagnostic
validity and therapeutic utility. Empirical studies support the
possible validity of mixed states in which manic episode criteria are
met with two or more depressive criteria (dysphoric mania) [4].
Using this definition, for instance, one study demonstrated greater
treatment response with valproate than with lithium [5]. Other
clinical studies suggest that a mixed state may be present when
major depressive episode (MDE) criteria are met with at least one
manic criterion (such as racing thoughts) [6,7]. In those clinical
studies, such mixed states appeared less responsive to antidepres-
sants and more responsive to adjunctive mood stabilizers [8].
Using the narrow DSM-IV criteria, less than 10% of episodes in
patients with bipolar disorder meet criteria for a mixed episode.
Using broader mixed states criteria, incorporating the clinical
features of dysphoric mania and agitated depression, data suggest
that about 50% of episodes in bipolar disorder would be
diagnosable as mixed states [7].
One study found that only 54% of 143 broadly defined mixed
states (using Kraepelinian definitions) met DSM-III-R criteria for
a mixed episode [9]. The concept of the depressive mixed state is
thus provisional, and not part of DSM definitions.
It should be noted that this study of the depressive mixed state
differs from a study of ‘‘agitated depression.’’ The concept of
agitated depression does not have a consensus definition; usually it
entails a MDE with at least psychomotor agitation. Our definition
of depressive mixed state is more than simply psychomotor
agitation along with depression: there must also be one or two
other manic symptoms (depending on the definition). Three or
more manic symptoms would define the condition as a DSM-IV
mixed episode. Thus the depressive mixed state is a subthreshold
DSM-IV mixed episode. Studies suggest that the majority of
persons with a depressive mixed state have bipolar disorder type
II, but a substantial group will also have MDD, according to
DSM-IV criteria [7].
The purpose of this study was to examine the efficacy of
ziprasidone for the depressive mixed state in patients with bipolar
or unipolar depression. This was the first double-blind randomized
clinical trial of any medication in the depressive mixed state.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. This five-site, block randomized, double-blinded,
placebo-controlled study analyzed 73 patients who were random-
ized to ziprasidone or placebo for 6 weeks between November
2006 and September 2009. The study was approved by the
Institutional Review Boards at each participating site (Tufts
Medical Center, Cambridge Health Alliance, Emory University,
Northwestern University, and Duke University). Each patient was
diagnosed with either bipolar disorder type II or major depressive
disorder (MDD) and also met DSM-IV criteria for a MDE, while
presenting 2 or 3 (but not more nor less) DSM-IV manic criteria.
They did not meet DSM-IV criteria for a mixed or manic episode.
Randomization was stratified by two factors: subtype of depressive
disorder (bipolar type II vs. MDD), and presence or absence of
rapid cycling. Research pharmacists generated the allocation
sequence and assigned participants to their groups. No research
procedures were performed without research staff first obtaining
signed informed consent from each patient. Study visits occurred
weekly for six weeks. Ziprasidone dosing began at 40 mg/day and
was increased by 20–40 mg weekly based on target symptoms and
tolerability with a target range of 80–160 mg/day of ziprasidone.
Baseline psychotropic drugs were unchanged throughout the
study.
Interviews and rating scales used included the Structured
Clinical Interview for DSM-IV Axis I Disorders-Patient Edition
(SCID) [10], the Montgomery A ˚sberg Depression Rating Scale
(MADRS) [11], the Mania Rating Scale from SADS-C (MRS)
[12], the Clinical Global Impression for Bipolar Disorder (CGI-
BP) [13], Global Assessment of Functioning (GAF) [14],
Systematic Assessment for Treatment Emergent Events (SAF-
TEE), the Barnes Akathisia Scale (BAS) [15], and the Simpson-
Angus Scale (SAS) [16].
Laboratory tests, consisting of complete blood count (CBC) with
differential, biochemistry profile, ECG and pregnancy test, were
conducted prior to the acute phase and at study termination.
Physical examination and vital signs were assessed at study
screening and termination visits. Patient termination occurred if
the patient experienced a worsening of MADRS scores greater
than 30% above the baseline score in two successive visits, if MRS
.20 in two successive visits, if suicidal ideation worsened as
determined by a MADRS suicide item of $3 in two successive
visits, or based on clinician judgment or patient preference.
Inclusion criteria for the study were as follows: male or female;
aged 18–65 years; current DSM-IV diagnosis of bipolar disorder
type II or MDD; currently meeting DSM-IV criteria for a MDE
while presenting with 2 or 3 DSM-IV manic criteria; if female,
nonpregnant/nonlactating; if sexually active using adequate
contraception; not psychotic and no cognitive impairment.
Specific mania criteria used are presented in the results. Minimum
duration of the episode followed the standard DSM-IV definition
of a MDE, namely 2 weeks or longer.
Exclusion criteria for the study were as follows: current
substance abuse in the previous month or relapse to substance
abuse during the study (as defined by meeting DSM-IV criteria);
medically unstable as judged by the study investigators; lack of
capacity to provide informed, written consent; previous intoler-
ance to ziprasidone or current use of ziprasidone at study baseline
or within 3 months of study entry; serious suicidality as evidenced
by score of 3 or greater on suicide item of MADRS; previous
diagnosed cardiac arrhythmias; current psychotic MDE; history of
potentially lethal suicide attempt.
The primary endpoint measured MADRS scores over weeks in
enrolled patients. Secondary measures tracked changes in CGI
and MRS scores, a priori subgroup analyses based on monother-
apy versus adjunctive therapy, and MDD versus bipolar type II
diagnostic subtypes. Treatment response was defined as 50%
improvement in MADRS and in MRS. Treatment remission was
defined as MADRS #9 and YMRS #11.
Power analysis, with b=0.20 and two-tailed a=0.05, was based
on pilot studies previously conducted for the mania registration
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scores, with about ten point improvement with drug over placebo.
Based on the available pilot data, a projected standard error of the
mean difference was assumed to range from equivalent to the
mean difference to twice as much as the mean difference (5–
15 points), producing a projected sample size of about 100
patients. After about three years of recruitment, the study was
terminated with a somewhat smaller overall sample after the
recruitment period could not be extended.
All baseline measures between treatment arms were compared
with endpoint measures. Effect sizes along with their 95%
confidence intervals were reported. The proportions of subjects
who improved reaching response/remission between the treat-
ment arms were compared using chi-square and Fisher exact test
statistics at endpoint. The main statistical analysis involved the use
of a linear mixed effects repeated measures model. To account for
the correlated nature of the data, we analyzed patients’ data as
repeated measures (using unrestricted covariance structure) and
included site of data collection as a random effect. Backward
selection procedure was used to select important predictors. The
primary model was built using MADRS scores over time as the
response variable, ziprasidone (drug) as the main explanatory
variable, and weeks (time) and its interaction with drug arm as the
dependent variables in the model.
A secondary exploratory analysis was performed with baseline
measures (MADRS, race, diagnosis, and interaction between
diagnosis and drug). Even though race and baseline severity were
only marginally significant, they were forced into the model due to
the significant differences in the racial composition of the two
treatment arm groups. When analyzed with adjustment for race
and baseline severity of depression, the overall results did not differ
notably. Model assumptions were verified. Sensitivity analysis
assessing robustness of results excluding one outlier data point was
done. The only notable difference from the original results was the
change from marginality (p=0.104) to significance (p=0.023) in
the difference between temporal patterns in the MADRS scores
for the two treatment arms. To address this issue we analyzed the
data slices separately for each week and found that the treatment
effect was significant at weeks 3, 5, and 6, and marginally
significant at week 4. Analyses were completed in Stata 11
(StataCorp LP, College Station, TX), and SAS 9.2 (SAS Institute
Inc., Cary, NC).
Dropout rates were not significantly different overall (attrition
was 19% of the ziprasidone group versus 21% of the placebo
group) and over time of the study; for dropouts by randomization
arm and CONSORT data see Figure S1.
In the two a priori secondary subgroup analyses, we assessed
treatment response by diagnostic subtype, and by concomitant
medications used (comparing those taking mood stabilizer or
antidepressant versus not). Since this study was powered for the
primary outcome only, we kept this marginally significant
interaction in the model and assessed these secondary moderators
of outcome through separate descriptive stratified analyses, with
mean differences or relative risks and confidence intervals.
Results
Clinical and demographic characteristics of the sample are
provided in Table 1. Specific mania criteria identified were as
follows, in descending order of frequency: flight of ideas (59%),
distractibility (58%), decreased need for sleep (43%), impulsive
behavior (27%), pressured speech/increased talkativeness (24%),
increased goal-directed activities (22%), and grandiosity (15%).
Thus, the most common presentation was an acute MDE with
flight of ideas, distractibility, and decreased need for sleep.
As seen in Table 2 and Figure 1, there was a very significant
effect of ziprasidone (p=0.0038), weeks from baseline (p,0.001),
and week*drug interaction (p=0.0447). Table 3 shows raw
outcome data from baseline to endpoint for the various rating
scales. Treatment response by categorical group was 52.9% for
ziprasidone versus 28.9% for placebo (x
2=4.29, df=1, p=0.04).
Treatment remission by categorical group was 50.0% for
ziprasidone versus 18.4% for placebo (x
2=8.05, df=1,
p=0.0045). MRS scores did not change appreciably over time
in both groups (Table 3, Figure 2).
In secondary exploratory analyses (Appendix S1, Appendix S2
and Appendix S3), it was observed that while baseline MADRS
was not notably different between drug and placebo groups, it was
strong in predicting further MADRS scores (p,0.0001). MADRS
scores exhibited significant changes over time in both groups
(p,0.001), as well as marginally differential temporal changes
between drug and placebo groups (p=0.104, which became
p=0.022 when outlier observation was excluded). The effect of
ziprasidone on MADRS scores was significantly different in the
two diagnoses subtypes (p=0.036), with more benefit in type II
bipolar disorder than MDD. Appendix S3 provides the week by
week effect estimates for the adjusted results in the mixed effects
regression model.
When tolerability to the regimen was investigated, there was no
significant weight change from baseline to endpoint in the
ziprasidone versus the placebo group (0.5 vs. 0.6 lbs). Akathisia
rates (defined as BAS scores .2) did not increase (ziprasidone,
initial=8.8%, endpoint=11.8%; placebo, initial=21.0%, end-
point=13.2%). Other extrapyramidal symptom rates (defined as
SAS .2) also did not increase (ziprasidone, initial=5.8%,
endpoint=3.0%; placebo, initial=10.8%, endpoint=13.16%).
Side effects reported by 5% or more subjects were headache
(n=7) and drowsiness (n=6) in the drug group and headache
(n=5) and drowsiness (n=5) in the placebo group. Side effects
were reported in 54.8% of the ziprasidone group and 56.3% of the
placebo group. Eleven (15.2%) patients terminated from the study,
6 for side effects (akathisia, sedation, migraines, chest pain, n=1
each, n=2 nonspecific) and 5 for other reasons (lack of efficacy
n=2; withdrawal of consent, noncompliance with appointments,
and legal arrest unrelated to ziprasidone, n=1 each). Average
dose did not differ significantly between ziprasidone (129.7 mg)
and placebo (126.1 mg) groups.
Discussion
Ziprasidone was effective and relatively tolerable in this first
randomized clinical trial of any medication for the acute
depressive mixed state. These results provide preliminary support
for both the nosological validity and the practical utility of a
broadening of the concept of mixed mood episodes beyond
current DSM constraints. Our definition of a depressive mixed
state is provisional, and outside the DSM-IV framework. In
secondary analyses, ziprasidone appeared somewhat more consis-
tently effective in bipolar disorder type II than in MDD, but no
notable difference was seen between monotherapy versus
adjunctive use with antidepressants or mood stabilizers.
The clinical interpretation of the statistical results of the mixed
effects regression model involve the following: Patients improved
in both ziprasidone and placebo groups over the course of the six
weeks of follow-up. Improvement with placebo likely reflects
natural history of bipolar disorder, namely, that all episodes
eventually end spontaneously, with depressive episodes usually
Ziprasidone for the Acute Depressive Mixed State
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been depressed for at least two weeks before entry into the study,
some would recover spontaneously over the course of the next one
to two months during the study. This clinical reality explains the
statistical result of an effect of weeks from baseline. The week by
drug interaction effect reflects the fact that this natural recovery was
enhanced by treatment with ziprasidone, as opposed to no active
treatment (placebo reflecting natural history alone). The independent
effect of ziprasidone, irrespective of duration of follow-up, is also
reflected in the statistical finding of a significant effect of the drug in the
mixed effect regression model. In sum, patients recover gradually over
time, but this recovery is enhanced by treatment with ziprasidone.
There are no previous randomized studies assessing neuroleptic
response in the depressive mixed state, but studies have previously
shown benefit with neuroleptics in dysphoric mania (DSM-defined
mania with subsyndromal depressive symptoms). Perhaps any type
of mixed state, whether predominantly depressive or predomi-
nantly manic, will be more responsive to neuroleptics [8]. It could
also be that ziprasidone may be more preferentially effective in the
depressive mixed state, due to its biochemical properties,
consisting of high serotonin and norepinephrine reuptake
properties with high 5HT-1A partial agonism (similar to what is
seen with some antidepressant classes) [18]. This possibility is
interesting especially given the inefficacy of ziprasidone in three
studies of DSM-IV defined bipolar depression which includes pure
depressive states (without any manic symptoms) and depressive
mixed states (depression with some manic symptoms). In two
monotherapy, similarly designed, randomized, double-blind,
placebo- controlled six-week trials of ziprasidone (dose 40–
160 mg/day) that included 900 subjects with adult bipolar I
depression assigned to treatment [19], ziprasidone (Study 1 mean
dose in low dose group=54 mg/day, n=540; mean dose in high
dose group=113 mg/day; Study 2 mean dose=84 mg/day,
n=360) failed to separate from placebo on the primary outcome
measure of change in total MADRS score from baseline to week 6
in mixed model repeated measures analyses of intent-to-treat
populations. Secondary analyses showed that in both studies
response rates ($50% improvement from baseline MADRS scores)
were similar in the ziprasidone and placebo groups (in study 1:53%
for ziprasidone 40–80 mg/d vs 46% for ziprasidone 80–160 mg/d
vs 49% for placebo; in study 2:53% vs 51% for ziprasidone vs.
placebo respectively). A third adjunctive study (in which ziprasi-
done, 40–160 mg/d, was added to the mood stabilizers lithium,
valproate or lamotrigine), was also a randomized, placebo-
controlled, six-week trial. In this study of 298 randomized subjects,
there were no significant differences between ziprasidone (mean
dose=89 mg/day) and placebo on the primary outcome measure
of change in total MADRS score from baseline to week 6
(mean6standard error 213.2461.24 vs 212.8861.08 for ziprasi-
Table 1. Clinical and Demographic Characteristics of the
Sample.
Ziprasidone
(n=35) Placebo (n=38)
Age (mean6SD, years) 39.1611.9 38.7612.7
Gender, % (n)
Male 47.1 (16) 47.4 (18)
Female 52.9 (18) 52.6 (20)
Race, % (n)
Non-caucasian 73.5 (25) 44.7 (17)
Caucasian 26.5 (9) 55.3 (21)
Education Level, % (n)
High School 60.0 (18) 59.4 (19)
Some College 30.0 (9) 18.8 (6)
Undergradute Degree 10.0 (3) 12.5 (4)
Graduate Degree 0 (0) 9.4 (3)
Diagnosis, % (n)
MDD 44.1 (15) 36.8 (14)
BD Type II 55.9 (19) 63.2 (24)
Concurrent Medications, % (n)
None 55.9 (20) 44.7 (17)
Antidepressants 35.3 (11) 44.7 (17)
Mood Stabilizers 0.0 (0) 7.9 (3)
Antidepressants & Mood
Stabilizers
8.8 (3) 2.6 (1)
Rapid Cycling, % (n)
Non-rapid cyclers 80.0 (24) 74.2 (23)
Rapid cyclers 20.0 (6) 25.8 (8)
Past Substance Abuse, % (n)
None 43.3 (13) 56.3 (18)
Positive History 56.7 (17) 43.3 (13)
SD=standard deviation, MDD=major depressive disorder, BD=bipolar
disorder.
doi:10.1371/journal.pone.0034757.t001
Table 2. Final ANOVA table of model without baseline
adjustments.
Effect
Estimate
(b) DF DF F Value p-Value
Drug
(Ziprasidone)
21.53 1 419 8.49 0.0038
Week 24.66 6 419 11.85 ,.0001
Week*drug 20.88 6 419 2.17 0.0447
DF= degrees of freedom, ANOVA=Analysis of variance, b=effect estimate.
doi:10.1371/journal.pone.0034757.t002
Figure 1. Ziprasidone vs Placebo: 6 week change in MADRS
(SD) from baseline.
doi:10.1371/journal.pone.0034757.g001
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outcome of change from baseline to week 6 in CGI-S scores
(mean6standard error 21.0460.2 for both groups, p=.722).
There was no difference in efficacy across groups when subdivided
by mood stabilizer. These monotherapy data have been reported in
research conferences [20], and the adjunctive study has been
published [19]. Dosing may also be relevant: in these negative
studies, the mean ziprasidone dose was 89.8629.1 mg/day,
whereas in our study, the dose was higher (129.7645.3 mg/day).
Previous studies have suggested that DSM-defined MDEs involve
the depressive mixed state (presence of manic symptoms) in 25–50%
of cases [21,22]. If this is so, then perhaps this study, combined with
the other studies showing lack of benefit in DSM-defined bipolar
depression, demonstrates that ziprasidone may be preferentially
effective in the depressive mixed state, but not in pure bipolar
depression. The lack of benefit seen in the DSM-defined bipolar
depressionstudiesmaythushavebeenduetoawateringdownofthe
benefit in the 25–50% of subjects with depressive mixed states by
lack of benefit in the 50–75% of subjects with pure depressive states.
The clinical implications of this possibility include the diagnostic
importance of assessing all depressed patients for current manic
symptoms, irrespective of whether or not they are diagnosable
with bipolar disorder in the past, and irrespective of whether or
not concurrent manic symptoms meet DSM-defined thresholds for
mania or hypomania [6,7]. Thus, depression with flight of ideas
and brief periods of hyperactivity (decreased need for sleep) would
likely be responsive to ziprasidone, whereas pure melancholic
depression without any flight of ideas and with constant low
energy would be less responsive. It may be, based on our
secondary outcomes, that there are still differences between mixed
depression in MDD versus bipolar disorder type II.
All studies have limitations, and in this case one potential
limitation in relation to secondary analyses would be sample size.
The randomized study design should account for most potential
confounding effects, but residual confounding cannot be com-
pletely eliminated without larger studies. Additionally, sufficient
assessment of the integrity of double blind procedure was not
completed. Replication of these results is also needed to confirm
validity and generalizability in other samples.
Conclusion
We observed a statistically significant difference between ziprasi-
d o n ea n dp l a c e b o ,e s p e c i a l l yi nt y p eI Ib i p o l a rd i s o r d e r ,i nt h i sf i r s t
randomized study of any medication for the depressive mixed state.
These results provide preliminary support for both the nosological
validity and the practical utility of a broadening of the concept of
mixed mood episodes. Further research will need to clarify the specific
nature of such potential mixed mood states, as well as their treatment.
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Table 3. Clinical Response of the Sample.
Outcome Ziprasidone (n=35) Placebo (n=38) Ziprasidone vs. Placebo
Baseline,
mean ±SD
Endpoint,
mean ±SD
Baseline,
mean ±SD
Endpoint,
mean ±SD
Outcome Change{
Difference [95% CI]
MADRS 23.466.5 12.0610.9 25.167.9 19.269.3 5.4 [0.6, 10.2]*{
MRS 8.466.1 4.765.2 8.866.2 6.565.1 1.5 [21.1, 4.0]
CGI 4.060.9 2.861.2 4.160.9 3.561.1 0.5 [20.1, 1.1]
GAF 56.765.9 65.869.3 56.265.4 60.967.9 4.4 [0.2, 8.6]*
SD=Standard deviation, MADRS=Montgomery-A ˚sberg Depression Rating Scale, MRS=Mania Rating Scale, CGI=Clinical Global Impressions Scale, GAF=Global
Assessment of Functioning Scale.
*p,0.05.
{Outcome change=Change of each measure from baseline to endpoint.
{F=8.273.
doi:10.1371/journal.pone.0034757.t003
Figure 2. Ziprasidone vs Placebo: 6 week change in MRS (SD)
from baseline.
doi:10.1371/journal.pone.0034757.g002
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